Elsevier

Journal of Thoracic Oncology

Volume 3, Issue 2, February 2008, Pages 107-110
Journal of Thoracic Oncology

Pathway of the Month
Inflammation, Epithelial to Mesenchymal Transition, and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance

https://doi.org/10.1097/JTO.0b013e3181630eceGet rights and content
Under an Elsevier user license
open archive

Inflammation is an important contributor to lung tumor development and progression. In addition, inflammatory signaling may promote epithelial to mesenchymal transition, development of aggressive metastatic tumor phenotypes, and play a role in resistance to targeted therapies. New insights in inflammatory signaling have led to the evaluation of combination therapies that target these specific pathways. In addition to developing the optimal combination of targeted agents, biomarker-based selection of patients who will likely benefit will be critical to the success of this strategy. Here we focus on the potential contribution of inflammatory mediator-induced resistance to epidermal growth factor receptor tyrosine kinase inhibitors.

Key Words

EGFR TK inhibitor
G-protein coupled receptors
Inflammation
Cyclooxygenase-2
PGE2
Epithelial to mesenchymal transition
Drug resistance
NSCLC

Cited by (0)

Disclosure: The authors declare no conflict of interest.